These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23415723)

  • 1. Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with Cytokeratin 19-derived CYFRA21-1 and pathological staging.
    Chen Q; Ge F; Cui W; Wang F; Yang Z; Guo Y; Li L; Bremner RM; Lin PP
    Clin Chim Acta; 2013 Apr; 419():57-61. PubMed ID: 23415723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.
    Yin J; Wang Y; Yin H; Chen W; Jin G; Ma H; Dai J; Chen J; Jiang Y; Wang H; Liu Z; Hu Z; Shen H
    PLoS One; 2015; 10(8):e0137076. PubMed ID: 26317979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
    Hang ZQ; Zheng MF; Huang JH
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
    Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
    Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment.
    Lapin M; Tjensvoll K; Oltedal S; Buhl T; Gilje B; Smaaland R; Nordgård O
    Sci Rep; 2016 Jul; 6():28929. PubMed ID: 27432216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
    Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
    J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of enrichment and detection of circulating tumor cells in NSCLC patients with immunomagnetic beads].
    Huang TH; Wang Z; Li Q; Li FR; Qi H; Zhou HX
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):676-80. PubMed ID: 18246797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R; Li R; Wang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method.
    Bozzetti C; Quaini F; Squadrilli A; Tiseo M; Frati C; Lagrasta C; Azzoni C; Bottarelli L; Galetti M; Alama A; Belletti S; Gatti R; Passaro A; Gradilone A; Cavazzoni A; Alfieri R; Petronini PG; Bonelli M; Falco A; Carubbi C; Pedrazzi G; Nizzoli R; Naldi N; Pinto C; Ardizzoni A
    PLoS One; 2015; 10(11):e0142891. PubMed ID: 26571236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYFRA21-1 as a serum tumor marker for follow-up patients with squamous cell lung carcinoma and oropharynx squamous cell carcinoma.
    Liu L; Liu B; Zhu LL; Li Y
    Biomark Med; 2013 Aug; 7(4):591-9. PubMed ID: 23905896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells in early breast cancer: A connection with vascular invasion.
    Maltoni R; Fici P; Amadori D; Gallerani G; Cocchi C; Zoli M; Rocca A; Cecconetto L; Folli S; Scarpi E; Serra P; Fabbri F
    Cancer Lett; 2015 Oct; 367(1):43-8. PubMed ID: 26184997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
    Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer.
    Chen X; Wang X; He H; Liu Z; Hu JF; Li W
    PLoS One; 2015; 10(5):e0126276. PubMed ID: 25996878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
    Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
    Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
    Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
    Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.